Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0013395 (dyspepsia)
 4,879 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Russell body gastritis is characterized by accumulation of plasma cells, filled with Russell bodies, in the gastric mucosa. Twelve cases have been reported in the English language medical literature. Its association with Helicobacter pylori gastritis or immunosuppression is known. The present case is the third to be reported in association with HIV infection. An 82-year-old male presented with dyspepsia, loose stools, loss of appetite and weight. Computed tomography scan showed esophageal and gastric wall thickening. Gastrointestinal endoscopy revealed gastritis. Microscopic examination of the biopsy revealed gastric mucosa with diffuse plasma cell infiltration in the lamina propria, associated with large eosinophilic Russell bodies. Immunoperoxidase stains revealed positivity for CD 138 and lambda and kappa chains. Special stain for Helicobacter pylori and immunostain for CD68 were negative. The differential diagnoses include plasmacytoma and mucosa associated lymphoid tissue (MALT) lymphoma with plasmacytic differentiation, which are entities with different prognostic and therapeutic implications.
Conn Med 2012 May
PMID:Russell body gastritis in an HIV positive patient: case report and review of literature. 2268 80

Spironolactone is a well-known multi-target drug and is specifically used for the treatment of high blood pressure and heart failure. It is also used for the treatment of edema, cirrhosis of the liver, malignant, pediatric, nephrosis and primary hyperaldosteronism. Spironolactone in association with thiazide diuretics treats hypertension and in association with furosemide treats bronchopulmonary dyspepsia. The therapeutic mechanism of action of spironolactone involves binding to intracellular mineralocorticoids receptors (MRs) in kidney epithelial cells, thereby inhibiting the binding of aldosterone. Since its first synthesis in 1957 there are several synthetic approaches have been reported throughout the years, Synthetic community has devoted efforts to improve the synthesis of spironolactone and to synthesize its analogues and derivatives. This review aims to provide comprehensive insight for the synthetic endeavors devoted towards the synthesis of a versatile drug spironolactone and its analogues/derivatives.
 ...
PMID:Synthetic approaches towards the multi target drug spironolactone and its potent analogues/derivatives. 2804 53